

USA Medicare Update

- **Five (5) USA Medicare Administrative Contractors (MACs) have each individually published proposed local coverage determinations (Draft LCDs) in relation to minimally invasive glaucoma surgery (MIGS) reimbursement coverage.**
- **The Draft LCDs propose reimbursement changes on the use of stents in conjunction with MIGS procedures but does not propose reimbursement changes for canaloplasty, as performed with the Company's iTrack™ and iTrack™ Advance devices.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), today advises that on May 30, 2024, five Medicare Administrative Contractors ("MACs"), Palmetto GBA, Celerian Group Company, National Government Services, Noridian Healthcare Solutions, and WPS Insurance Corporation, each individually published Draft LCDs.

The Draft LCDs addresses coverage indications for MIGS; aqueous stents (iStent, Hydrus) and supraconjunctival stents (XEN). Specifically, the Draft LCDs propose that stents in combination with a surgical MIGS procedure in the same patient eye, at the same time, will not be reimbursed.

Each MAC will provide a 45-day public comment period on the Draft LCDs, after which they determine whether to finalise the LCDs with or without change, or to retire the LCDs.

The Draft LCDs do not make specific reference to the reimbursement coverage for the Company's MIGS portfolio, iTrack™ and iTrack™ Advance, nor the Molteno3® portfolio and hence reimbursement for surgeries with these devices remains unchanged.

The Company's iTrack™ and iTrack™ Advance devices are cleared by the USA Food and Drug Administration (FDA) for the catheterization and viscodilation of Schlemm's canal for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma. The effectiveness of the iTrack™ and iTrack™ Advance devices does not rely on the concurrent placement of a MIGS stent.

The Company continues to engage with all industry stakeholders, including the MACs, to educate them on the efficacy of the Company's iTrack™, iTrack™ Advance and Molteno3® devices.

This release dated May 31, 2024, has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Company

Kate Hunt
Chief Commercial Officer
+61 404 080 679
khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com